Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study.
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study.
复制标题
DOI：
10.2147/dddt.s96893
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Kristen AV
中科院分区：
文献类型：
--
作者：
aus dem Siepen F;Bauer R;Aurich M;Buss SJ;Steen H;Altland K;Katus HA;Kristen AV
目前尚缺乏对野生型转甲状腺素淀粉样心肌病(wtATTR-CM)患者的病因治疗。最近的报告表明，表没食子儿茶素没食子酸酯(EGCG)是绿茶中含量最丰富的儿茶素，可能用于抑制淀粉样纤维的形成。我们试图调查服用绿茶提取物(GTE)后wtATTR-CM患者的心功能和心形态的变化。25例男性患者(71[；80岁])在每日服用含表没食子儿茶素没食子酸酯600 mg的GTE胶囊至少12个月前后进行临床检查、超声心动图、心脏磁共振成像(CMRI)和实验室检查。服药1年后，CMRI显示左室心肌质量显著下降6%(196[100；247]vs 180[85；237]g；P=0.03)，总胆固醇下降8.4%(191[118；267]vs 173[106；287]mg/dL；P=0.006)。CMRI测定的左心室射血分数(53%[33%；69%]vs 54%[28%；71%]；P=0.75)、左室壁厚度(17[13；21]vs 18[14；25]mm；P=0.1)、二尖瓣环平面收缩期离散度(10[5；23]vs 8[4；13]mm；P=0.3)无明显变化。这项研究支持服用GTE的wtATTR-CM患者的左心室质量稳定，这可能表明淀粉样原纤维减少。
Causative treatment of patients with wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is lacking. Recent reports indicate the potential use of epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, to inhibit amyloid fibril formation. We sought to investigate changes of cardiac function and morphology in patients with wtATTR-CM after consumption of green tea extract (GTE). Twenty-five male patients (71 [64; 80] years) with wtATTR-CM were submitted to clinical examination, echocardiography, cardiac magnetic resonance imaging (cMRI) (n=14), and laboratory testing before and after daily consumption of GTE capsules containing 600 mg epigallocatechin-3-gallate for at least 12 months. A significant decrease of left ventricular (LV) myocardial mass by 6% (196 [100; 247] vs 180 [85; 237] g; P=0.03) by cMRI and total cholesterol by 8.4% (191 [118; 267] vs 173 [106; 287] mg/dL; P=0.006) was observed after a 1-year period of GTE consumption. LV ejection fraction by cMRI (53% [33%; 69%] vs 54% [28%; 71%]; P=0.75), LV wall thickness (17 [13; 21] vs 18 [14; 25] mm; P=0.1), and mitral annular plane systolic excursion (10 [5; 23] vs 8 [4; 13] mm; P=0.3) by echocardiography remained unchanged. This study supports LV mass stabilization in patients with wtATTR-CM consuming GTE potentially indicating amyloid fibril reduction.